Equities research analysts expect Revance Therapeutics Inc (NASDAQ:RVNC) to report sales of $12.68 million for the current quarter, Zacks reports. Two analysts have made estimates for Revance Therapeutics’ earnings, with estimates ranging from $260,000.00 to $25.10 million. Revance Therapeutics reported sales of $80,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 15,750%. The firm is scheduled to report its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Revance Therapeutics will report full year sales of $12.68 million for the current fiscal year, with estimates ranging from $500,000.00 to $25.30 million. For the next financial year, analysts expect that the business will report sales of $1.65 million per share, with estimates ranging from $600,000.00 to $2.70 million. Zacks’ sales averages are an average based on a survey of research analysts that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the previous year, the company posted ($0.95) EPS. The company’s quarterly revenue was down 50.7% on a year-over-year basis.
Shares of Revance Therapeutics (NASDAQ:RVNC) traded up $0.40 during trading on Friday, hitting $34.10. 486,324 shares of the stock traded hands, compared to its average volume of 350,574. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45. The firm has a market cap of $1,201.43, a PE ratio of -8.63 and a beta of 1.36.
In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 10,000 shares of the company’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $31.50, for a total transaction of $315,000.00. Following the completion of the transaction, the chief financial officer now owns 82,954 shares in the company, valued at approximately $2,613,051. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO L Daniel Browne sold 27,283 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $31.43, for a total transaction of $857,504.69. Following the transaction, the chief executive officer now owns 131,208 shares of the company’s stock, valued at approximately $4,123,867.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,283 shares of company stock valued at $1,812,505. 18.86% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in RVNC. Alliancebernstein L.P. raised its position in Revance Therapeutics by 4,063.7% during the 4th quarter. Alliancebernstein L.P. now owns 907,695 shares of the biopharmaceutical company’s stock worth $32,450,000 after buying an additional 885,895 shares during the last quarter. Jennison Associates LLC raised its position in Revance Therapeutics by 127.1% during the 4th quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock worth $30,657,000 after buying an additional 480,008 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Revance Therapeutics during the 4th quarter worth $14,300,000. Senzar Asset Management LLC purchased a new position in Revance Therapeutics during the 4th quarter worth $8,450,000. Finally, Bank of New York Mellon Corp raised its position in Revance Therapeutics by 6.7% during the 4th quarter. Bank of New York Mellon Corp now owns 2,144,669 shares of the biopharmaceutical company’s stock worth $76,672,000 after buying an additional 135,356 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.